Chimeric VSV Vectors With Arenavirus GP for Safer Oncolytic Use
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing VSV-based oncolytic vectors face challenges such as neurotoxicity and rapid induction of neutralizing antibodies, limiting their repeated application in cancer therapy.
Innovation Solution
Development of VSV chimeric vectors that replace the envelope protein G with glycoproteins from Dandenong virus (DANDV), Mopeia virus (MOPV), Ippy virus (IPPYV), Latino virus (LATV), or Olivero virus (OLIVV), maintaining replicative capacity and cellular tropism while reducing neutralizing antibody induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild type VSV is used for oncolytic virotherapy, then broad receptor tropism and strong replicative capacity are achieved, but neurotoxicity and rapid induction of neutralizing antibodies occur
Solution Approach 1:
The patent extracts and removes the harmful VSV-G envelope protein gene from the viral genome, replacing it with a heterologous glycoprotein gene from DANDV or MOPV. This extraction eliminates the neurotoxicity associated with VSV-G while preserving the oncolytic properties of the virus platform.
Solution Approach 2:
The patent changes the envelope protein parameter by substituting VSV-G with arenavirus glycoproteins (DANDV-GP or MOPV-GP). This parameter change fundamentally alters the virus's interaction with neural cells, eliminating neurotoxicity while maintaining tumor cell infectivity through broad receptor tropism of the arenavirus glycoproteins.
2Reliability
If wild type VSV is used for oncolytic virotherapy, then strong CPE and immune response induction are achieved, but rapid induction of neutralizing antibodies limits repeated application
Solution Approach 1:
The patent extracts the VSV-G envelope protein, which is the primary target for neutralizing antibodies. By removing this immunodominant antigen while retaining other viral proteins that induce cytolytic T-cell responses, the virus maintains reliable immune activation against tumor antigens without rapidly inducing neutralizing antibodies that would block re-administration.
Solution Approach 2:
Instead of using the native VSV-G envelope protein that elicits strong neutralizing antibody responses, the patent inverts the approach by using heterologous arenavirus glycoproteins. This inversion changes the immune response profile from antibody-mediated neutralization to cell-mediated immunity, thereby extending the duration of therapeutic action and enabling repeated applications.
3Object-affected harmful factors
If VSV-G is replaced by LCMV-GP to eliminate neurotoxicity, then neurotoxicity is reduced, but neutralizing antibody induction remains a limitation
Solution Approach 1:
The patent changes the envelope protein parameter from LCMV-GP to arenavirus glycoproteins (DANDV-GP or MOPV-GP). This parameter change further reduces neutralizing antibody induction compared to LCMV-GP, as arenavirus glycoproteins elicit weaker humoral responses. This extends the duration of therapeutic action and enables repeated applications while maintaining the neurotoxicity elimination achieved by LCMV-GP.
Data Source
AI summary
The present invention relates to VSV chimeric vectors, characterized in that the vectors comprise a gene coding for a glycoprotein GP of the Dandenong virus (DANDV) or Mopeia vims (MOPV) and lack a functional gene coding for envelope protein G of the VSV. The invention also provides VSV chimeric vector systems. In addition, the invention relates to uses of the VSV chimeric vectors and systems of the invention, including the use in medicine such as in the treatment of solid tumors.